Analysts Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $81.43

MoonLake Immunotherapeutics (NASDAQ:MLTX) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $81.43.

A number of equities research analysts recently weighed in on MLTX shares. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Needham & Company LLC reissued a “buy” rating and issued a $62.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, September 12th. Finally, Wedbush restated an “outperform” rating and set a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, Director Simon Sturge sold 171,000 shares of the stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $53.72, for a total value of $9,186,120.00. Following the completion of the transaction, the director now owns 171,980 shares in the company, valued at $9,238,765.60. This represents a 49.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 12.02% of the stock is owned by company insiders.

Institutional Trading of MoonLake Immunotherapeutics

Institutional investors have recently made changes to their positions in the stock. US Bancorp DE bought a new stake in MoonLake Immunotherapeutics during the third quarter worth approximately $44,000. Quarry LP increased its position in shares of MoonLake Immunotherapeutics by 172.7% during the 2nd quarter. Quarry LP now owns 3,000 shares of the company’s stock valued at $132,000 after purchasing an additional 1,900 shares during the period. Barclays PLC raised its stake in shares of MoonLake Immunotherapeutics by 1,269.2% in the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after buying an additional 5,229 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of MoonLake Immunotherapeutics by 26.2% in the third quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock valued at $655,000 after buying an additional 2,700 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the third quarter valued at $706,000. 93.85% of the stock is owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Trading Up 1.0 %

Shares of MLTX opened at $52.67 on Wednesday. The firm has a market cap of $3.37 billion, a price-to-earnings ratio of -40.83 and a beta of 1.31. MoonLake Immunotherapeutics has a 52 week low of $37.55 and a 52 week high of $64.98. The stock has a 50 day moving average of $50.95 and a 200-day moving average of $47.86.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). During the same period in the previous year, the business earned ($0.18) EPS. On average, sell-side analysts predict that MoonLake Immunotherapeutics will post -1.74 earnings per share for the current fiscal year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.